Name
RF6-07: (T-DXd) + (P) vs (THP) for first-line (1L) treatment of patients with HER2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): patient-reported outcomes (PROs) from the DESTINY-Breast09 study - Commentary By: Giuseppe Curigliano, MD, PhD
Date & Time
Tuesday, December 2, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL